EA200501134A1 - Способ профилактики и лечения вирусных инфекций (варианты), фармацевтическая композиция (варианты) и лечебный набор - Google Patents

Способ профилактики и лечения вирусных инфекций (варианты), фармацевтическая композиция (варианты) и лечебный набор

Info

Publication number
EA200501134A1
EA200501134A1 EA200501134A EA200501134A EA200501134A1 EA 200501134 A1 EA200501134 A1 EA 200501134A1 EA 200501134 A EA200501134 A EA 200501134A EA 200501134 A EA200501134 A EA 200501134A EA 200501134 A1 EA200501134 A1 EA 200501134A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
options
variants
prevention
pharmaceutical composition
Prior art date
Application number
EA200501134A
Other languages
English (en)
Other versions
EA015145B1 (ru
Inventor
Теренс К. Дал
Марк М. Меннинг
Реза Олияй
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32776014&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200501134(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA200501134A1 publication Critical patent/EA200501134A1/ru
Publication of EA015145B1 publication Critical patent/EA015145B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Настоящее изобретение относится к терапевтическим комбинациям фумарата диизопропоксикарбонилоксиметилового эфира [2-(6-аминопурин-9-ил)-1-метилэтоксиметил]фосфоновой кислоты (тенофовир дизопроксил фумарат, тенофовир DF, TDF, Viread®) и (2R,5S,цис)-4-амино-5-фтор-1-(2-оксиметил-1,3-оксатиолан-5-ил)-(1H)-пиримидин-2-она (эмтрицитабин, Emtriva™, (-)-цис FTC) и их физиологически функциональным производным. Комбинации могут использоваться при лечении ВИЧ-инфекций, в том числе инфекций, вызванных мутантами ВИЧ, выработавшими устойчивость к нуклеозидным и ненуклеозидным ингибиторам. Представленное изобретение также касается фармацевтических составов и технологий приготовления вышеупомянутых смесей тенофовира дизопроксил фумарата и эмтрицитабина, и их физиологически функциональных производных, наряду с терапевтическими способами использования таких композиций и составов.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200501134A 2003-01-14 2004-01-13 Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции EA015145B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44024603P 2003-01-14 2003-01-14
US44030803P 2003-01-14 2003-01-14
PCT/US2004/000832 WO2004064845A1 (en) 2003-01-14 2004-01-13 Compositions and methods for combination antiviral therapy

Publications (2)

Publication Number Publication Date
EA200501134A1 true EA200501134A1 (ru) 2005-12-29
EA015145B1 EA015145B1 (ru) 2011-06-30

Family

ID=32776014

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201100293A EA201100293A1 (ru) 2003-01-14 2004-01-13 Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
EA200501134A EA015145B1 (ru) 2003-01-14 2004-01-13 Фармацевтическая композиция и пероральная фармацевтическая дозированная форма (варианты), проявляющие активность в отношении вич-инфекций, лечебный набор и таблетка и способ лечения или предотвращения симптомов или эффектов вич-инфекции

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201100293A EA201100293A1 (ru) 2003-01-14 2004-01-13 Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции

Country Status (26)

Country Link
US (11) US20060246130A1 (ru)
EP (4) EP1583542B9 (ru)
JP (8) JP4996241B2 (ru)
KR (3) KR20080032014A (ru)
CN (2) CN105596356A (ru)
AP (1) AP2089A (ru)
AT (1) ATE398455T1 (ru)
AU (3) AU2004206827A1 (ru)
BR (1) BRPI0406760A (ru)
CA (2) CA2512319A1 (ru)
CY (1) CY1108355T1 (ru)
DE (1) DE602004014470D1 (ru)
DK (1) DK1583542T3 (ru)
EA (2) EA201100293A1 (ru)
ES (1) ES2308136T3 (ru)
HK (1) HK1079122A1 (ru)
HR (2) HRP20050619A2 (ru)
IL (1) IL169243A (ru)
IS (1) IS7977A (ru)
MX (1) MXPA05007016A (ru)
NO (3) NO337917B1 (ru)
NZ (1) NZ540728A (ru)
PL (2) PL408254A1 (ru)
PT (1) PT1583542E (ru)
SI (1) SI1583542T1 (ru)
WO (2) WO2004064845A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2786524C2 (ru) * 2018-09-28 2022-12-21 Акционерное общество "БИОКАД" Ингибиторы рецептора эпидермального фактора роста

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
CN101068533B (zh) 2004-12-03 2011-04-27 默沙东公司 含有抗成核剂的药物组合物
JP2008535862A (ja) * 2005-04-08 2008-09-04 キメリクス，インコーポレイテッド ポックスウイルス感染の治療のための化合物、組成物および方法
EP1865967A4 (en) * 2005-04-08 2011-02-09 Chimerix Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND OTHER DISEASES
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US8340944B2 (en) 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US20080210748A1 (en) 2005-11-30 2008-09-04 Searete Llc, A Limited Liability Corporation Of The State Of Delaware, Systems and methods for receiving pathogen related information and responding
US7827042B2 (en) 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US7927787B2 (en) 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
US10296720B2 (en) 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
KR20080091767A (ko) * 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN101595046B (zh) * 2007-01-20 2012-01-25 默克专利有限公司 装有软胶囊的包装
WO2008096369A2 (en) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US20100196273A1 (en) * 2007-02-12 2010-08-05 Board Of Regents, University Of Texas System Novel agent for in vivo pet imaging of tumor proliferation
EP3150586B1 (en) 2007-02-23 2020-01-08 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
MY164765A (en) * 2007-10-10 2018-01-30 Avantor Performance Mat Llc Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
EP2240604B1 (en) 2008-01-18 2012-07-25 North Carolina State University Peptides and methods of use as therapeutics and screening agents
US8993542B2 (en) 2008-01-25 2015-03-31 Chimerix Inc. Methods of treating viral infections
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
HUE026380T2 (en) 2008-05-02 2016-06-28 Gilead Sciences Inc Use of solid carrier particle
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
PL2393485T3 (pl) 2009-02-06 2015-12-31 Gilead Sciences Inc Dwuwarstwowe tabletki zawierające elwitegrawir, kobicystat, emtrycytabinę i tenofowir
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
UA105556C2 (ru) * 2010-01-27 2014-05-26 Віів Гелскер Компані Комбинация соединений, содержащая ингибиторы вич интегразы с другими терапевтическими агентами
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
UY33312A (es) 2010-03-31 2011-10-31 Pharmasset Inc Fosforamidato de nucleosido de purina
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
BR112012024884A2 (pt) 2010-03-31 2016-10-18 Gilead Pharmasset Llc síntese estereosseletiva de ativos contendo fósforo
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES
EP2389929A1 (en) * 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of tenofovir
EP2579892A2 (en) 2010-06-09 2013-04-17 Vaccine Technologies, Incorporated Therapeutic immunization in hiv infected subjects receiving stable antiretroviral treatment
AU2011288091B2 (en) * 2010-08-01 2016-06-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystals of Tenofovir disoproxil fumarate
BR112013012245B1 (pt) * 2010-11-19 2022-09-27 Janssen Sciences Ireland Uc Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
US9550803B2 (en) 2011-05-06 2017-01-24 University Of Southern California Method to improve antiviral activity of nucleotide analogue drugs
EP2785184B1 (en) 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
ES2874774T3 (es) 2011-12-22 2021-11-05 Geron Corp Análogos de guanina como sustratos de telomerasa y afectores de la longitud de los telómeros
WO2013115916A1 (en) * 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
US20150105350A1 (en) 2012-02-03 2015-04-16 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
CN107312039B (zh) * 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
US9227990B2 (en) * 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
NZ718708A (en) 2012-12-21 2018-11-30 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN103127028A (zh) * 2013-03-14 2013-06-05 南京恒道医药科技有限公司 一种含有富马酸替诺福韦二吡呋酯的胶囊剂
HUE037347T2 (hu) 2013-07-12 2018-08-28 Gilead Sciences Inc Policiklusos karmaboilpiridon vegyületek és alkalmazásuk HIV fertõzések kezelésére
NO2865735T3 (ru) 2013-07-12 2018-07-21
WO2015028875A2 (en) * 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CZ2013985A3 (cs) * 2013-12-09 2015-06-17 Zentiva, K.S. Stabilní farmaceutická kompozice obsahující tenofovir disoproxil fumarát
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
AU2015245217A1 (en) 2014-04-08 2016-10-13 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising Emtricitabine, Tenofovir, Darunavir and Ritonavir
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (ru) 2014-06-20 2018-06-23
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
CN105399771B (zh) * 2014-07-21 2020-11-24 江苏豪森药业集团有限公司 替诺福韦前药晶型及其制备方法和用途
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
BR112017013858A2 (pt) 2014-12-26 2018-02-27 Univ Emory n4-hidroxicitidina e derivados e usos antivirais relacionados aos mesmos
JP2018509400A (ja) * 2015-03-27 2018-04-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ セムブラギリンを含む医薬製剤
SI3277691T1 (sl) 2015-04-02 2019-04-30 Gilead Sciences, Inc. Policiklične spojine karbamoilpiridona in njihova farmacevtska uporaba
EP3607939B1 (en) * 2015-06-30 2022-06-01 Gilead Sciences, Inc. Pharmaceutical formulations comprising tenofovir and emtricitabine
TWI620754B (zh) * 2015-08-26 2018-04-11 Method for preparing amino phosphate derivative and preparation method thereof
KR102606625B1 (ko) * 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
EP3390413B1 (en) 2015-12-15 2020-08-19 Merck Sharp & Dohme Corp. Antiviral oxime phosphoramide compounds
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
US10449208B2 (en) 2016-08-25 2019-10-22 Merck Sharp & Dohme Corp. Antiviral prodrugs of tenofovir
EP3532069A4 (en) 2016-10-26 2020-05-13 Merck Sharp & Dohme Corp. ARYL-AMIDE PHOSPHODIAMIDE COMPOUNDS ANTIVIRALS
TR201617448A2 (tr) * 2016-11-29 2018-06-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovi̇r ve emtri̇si̇tabi̇n i̇çeren kati oral farmasöti̇k bi̇leşi̇mler
KR20190100249A (ko) 2016-12-22 2019-08-28 머크 샤프 앤드 돔 코포레이션 항바이러스 벤질-아민 포스포디아미드 화합물
CN106749254B (zh) * 2017-01-10 2018-05-25 青岛科技大学 一种6-氨基嘌呤乙基萘乙酸酯类化合物及其作为植物生长调节剂的用途
WO2018153977A1 (en) * 2017-02-24 2018-08-30 Hexal Ag Stable composition of tenofovir alafenamide
GB201705087D0 (en) * 2017-03-30 2017-05-17 Univ Liverpool Method for producing a liquid composition
CA3060222A1 (en) * 2017-04-18 2018-10-25 Cipla Limited Combination therapy for use in treating retroviral infections
RU2662160C9 (ru) * 2017-07-03 2018-10-22 Александрович Иващенко Андрей Комбинированный лекарственный препарат для терапии вирусных инфекций
KR102077060B1 (ko) * 2017-07-14 2020-02-13 주식회사 종근당 테노포비어 디소프록실 아스파르트산 염을 포함하는 약제학적 조성물
RU2666727C1 (ru) * 2017-07-18 2018-09-12 Андрей Александрович Иващенко Ингибитор вируса гепатита В (ВГВ)
TR201713954A2 (tr) 2017-09-20 2019-04-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
WO2019113462A1 (en) 2017-12-07 2019-06-13 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2020018399A1 (en) 2018-07-19 2020-01-23 Merck Sharp & Dohme Corp. Phosphinic amide prodrugs of tenofovir
RU2726210C2 (ru) * 2018-12-27 2020-07-09 Общество С Ограниченной Ответственностью "Пролонгированные Лекарства" Комбинация противовирусных средств, набор и способ лечения на ее основе
CN110261631A (zh) * 2019-07-26 2019-09-20 重庆德方信息技术有限公司 用于健康检测装置的滴液机构
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN113880898B (zh) * 2020-10-30 2023-07-25 杭州拉林智能科技有限公司 黄酮苷-有机胺类抗微生物剂复盐化合物及其制备方法和应用

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US568164A (en) 1896-09-22 Motor attachment for bicycles
CH389608A (de) 1960-01-19 1965-03-31 Sandoz Ag Verfahren zur Herstellung von neuen Äthern
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US3622677A (en) 1969-07-07 1971-11-23 Staley Mfg Co A E Compressed tablets containing compacted starch as binder-disintegrant ingredient
CH531000A (de) 1970-03-11 1972-11-30 Sandoz Ag Verfahren zur Herstellung neuer Benzocycloheptathiophene
US3994974A (en) 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
US4003878A (en) 1972-12-07 1977-01-18 Avtex Fibers Inc. Method of preparing an alkali-metal salt of an alkoxysulfonated benzoic acid glycol ester
GB1523865A (en) 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
DE2645710C2 (de) 1976-10-09 1985-06-27 Merck Patent Gmbh, 6100 Darmstadt Phenoxy-amino-propanole, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung
US4384005A (en) 1980-09-26 1983-05-17 General Foods Corporation Non-friable, readily-soluble, compressed tablets and process for preparing same
EP0054512A3 (de) 1980-12-12 1983-08-03 Ciba-Geigy Ag Cephalosporinester, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
US4355032B2 (en) 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
JPS5879983A (ja) 1981-11-06 1983-05-13 Kanebo Ltd 新規なベンズイミダゾ−ル誘導体、その製造法およびその医薬組成物
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4476248A (en) 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen
DE3485225D1 (de) 1983-08-18 1991-12-05 Beecham Group Plc Antivirale guanin-derivate.
US5155268A (en) 1984-05-04 1992-10-13 The Upjohn Company Antiarrhythmic N-aminoalkylene alkyl and aryl sulfonamides
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
CS263951B1 (en) * 1985-04-25 1989-05-12 Antonin Holy 9-(phosponylmethoxyalkyl)adenines and method of their preparation
CS263952B1 (en) * 1985-04-25 1989-05-12 Holy Antonin Remedy with antiviral effect
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
IL84477A (en) 1986-11-18 1995-12-08 Bristol Myers Squibb Co History of Phosphonomethoxyalkylene Purinopyrimidine and Pharmaceutical Preparations Containing Them
DE3790883T1 (ru) 1987-01-20 1988-12-08
GB8719367D0 (en) 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
ZA885709B (en) 1987-08-19 1989-04-26 Fujisawa Pharmaceutical Co Novel crystalline 7-(2-(2-aminothiazol-4-yl)-2-hydroxyiminoacetamido)-3-vinyl-3-cephem-4-carboxylic acid(syn isomer)
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6175008B1 (en) 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5466806A (en) 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5453503A (en) 1988-10-11 1995-09-26 Eli Lilly And Company Azetidinone intermediates to carbacephalosporins and process
CA2001715C (en) 1988-11-14 1999-12-28 Muzammil M. Mansuri Carbocyclic nucleosides and nucleotides
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
US5177064A (en) 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5356886A (en) 1990-07-19 1994-10-18 Beecham Group P.L.C. Antiviral phosphono-alken derivatives of purines
CA2088363C (en) 1990-08-10 2002-05-28 Purushotham Vemishetti Process for the preparation of nucleotides
ATE167679T1 (de) * 1990-09-14 1998-07-15 Acad Of Science Czech Republic Wirkstoffvorläufer von phosphonaten
CA2054126A1 (en) 1990-10-26 1992-04-27 Michiyuki Sendai Cephem compounds, their production and use
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
US5208221A (en) 1990-11-29 1993-05-04 Bristol-Myers Squibb Company Antiviral (phosphonomethoxy) methoxy purine/pyrimidine derivatives
GB9026164D0 (en) 1990-12-01 1991-01-16 Beecham Group Plc Pharmaceuticals
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
NZ241625A (en) 1991-02-22 1996-03-26 Univ Emory 1,3-oxathiolane derivatives, anti-viral compositions containing such and method of resolving racemic mixture of enantiomers
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
SK279262B6 (sk) 1991-05-16 1998-08-05 Glaxo Group Limited Protivírusová zmes, farmaceutický prostriedok s je
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US6177435B1 (en) 1992-05-13 2001-01-23 Glaxo Wellcome Inc. Therapeutic combinations
EP0647649B1 (en) 1992-06-23 1998-11-11 Yamanouchi Pharmaceutical Co. Ltd. Novel crystal of monohydrate of heterocyclic bis(phosphonic acid) derivative
US5532225A (en) 1992-07-31 1996-07-02 Sri International Acyclic purine phosphonate nucleotide analogs as antiviral agents, and related synthetic methods
US5432172A (en) 1992-08-03 1995-07-11 The Research Foundation Of State University Of New York Biological applications of alkaloids derived from the tunicate Eudistoma sp.
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
CA2107644A1 (en) 1992-10-28 1994-04-29 David R. Magnin .alpha.-phosphonosulfonae squalene synthetase inhibitors and methd
WO1994018215A1 (en) 1993-02-03 1994-08-18 Gensia, Inc. Adenosine kinase inhibitors comprising lyxofuranosyl derivatives
US5514798A (en) 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
ATE199906T1 (de) 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
AU690587B2 (en) 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
WO1995032957A1 (en) 1994-05-27 1995-12-07 Astra Aktiebolag Novel ethoxycarbonyloxymethyl derivatives of substituted benzimidazoles
US5514557A (en) 1994-06-06 1996-05-07 Genetic Testing Institute Inc. Method and kit for detecting antibodies specific for HLA and/or platelet glycoproteins
PE32296A1 (es) 1994-07-28 1996-08-07 Hoffmann La Roche Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
US5512596A (en) 1994-09-02 1996-04-30 Gilead Sciences, Inc. Aromatic compounds
US5486806A (en) * 1994-11-09 1996-01-23 Firari; Harold A. Anti-hijacking and theft prevention device for motor vehicles
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5618964A (en) 1995-06-07 1997-04-08 Bristol-Myers Squibb Company Prodrug esters of phosphonosulfonate squalene synthetase inhibitors and method
JPH11507632A (ja) 1995-06-07 1999-07-06 トリメリス，インコーポレーテッド 併用療法を用いたｈｉｖおよび他のウイルス感染の治療
CA2261619C (en) 1996-07-26 2006-05-23 Gilead Sciences, Inc. Nucleotide analogs
US5733788A (en) * 1996-07-26 1998-03-31 Gilead Sciences, Inc. PMPA preparation
US5922695A (en) * 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
AU4428397A (en) 1996-09-20 1998-04-14 Warner-Lambert Company Oral compositions containing a zinc compound
US6113920A (en) 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
GB9622681D0 (en) 1996-10-31 1997-01-08 Glaxo Group Ltd Pharmaceutical compositions
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
US6143877A (en) 1997-04-30 2000-11-07 Epoch Pharmaceuticals, Inc. Oligonucleotides including pyrazolo[3,4-D]pyrimidine bases, bound in double stranded nucleic acids
CN1763057B (zh) * 1997-07-25 2012-10-17 吉尔利德科学股份有限公司 核苷酸类似物组合物
US5935946A (en) * 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
ZA986614B (en) 1997-07-25 1999-01-27 Gilead Sciences Nucleotide analog composition
US6270957B1 (en) * 1997-08-26 2001-08-07 Wisconsin Alumni Research Foundation Non-Imuunosuppressive cyclosporins and their use in the prevention and treatment of HIV infection
CO4970782A1 (es) 1997-11-13 2000-11-07 Merck & Co Inc Terapia combinada para el tratamiento del sida
US6087383A (en) * 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6127121A (en) 1998-04-03 2000-10-03 Epoch Pharmaceuticals, Inc. Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
UA72207C2 (ru) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтическая композиция эфавиренца в сочетании с ингредиентами, обеспечивающими распад таблеток, и способ изготовления быстрорастворимых таблеток и капсул эфавиренца
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
EP1332757B1 (en) 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (es) 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
CA2335617C (en) 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
DE69921829T2 (de) * 1998-08-12 2005-10-27 Gilead Sciences, Inc., Foster City Verfahren zur herstellung von 1,3-oxathiolannukleoside
GB9820420D0 (en) 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
PT1380303E (pt) * 1998-11-02 2008-11-03 Gilead Sciences Inc Terapia de combinação para tratar o vírus de hepatite b
GB9909154D0 (en) 1999-04-22 1999-06-16 Nippon Glaxo Limited Pharmaceutical formulation
US6660845B1 (en) 1999-11-23 2003-12-09 Epoch Biosciences, Inc. Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
ATE308982T1 (de) 2000-02-02 2005-11-15 Dorian Bevec Aromatisches guanylhydrazon zur behandlung resistenter viraler infektionen
DE60115870T3 (de) * 2000-02-29 2010-07-29 Bristol-Myers Squibb Co. Niedrig dosierte entecavir-formulierung und deren verwendung
ES2536972T5 (es) * 2000-07-21 2022-04-06 Gilead Sciences Inc Profármacos de análogos de nucleótidos de fosfonato y métodos para seleccionar y preparar los mismos
CN1501828A (zh) 2000-12-15 2004-06-02 ������˹ҩƷ��˾ 用肌苷一磷酸脱氢酶抑制剂进行的dapd联合治疗
US6900315B2 (en) 2001-02-06 2005-05-31 Yale University 2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
CN102942563A (zh) 2001-03-01 2013-02-27 基利得科学公司 顺-ftc的多晶型物及其它晶型
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030124186A1 (en) 2001-11-27 2003-07-03 Hussain Munir A. Efavirenz tablet formulation having unique biopharmaceutical characteristics
RS52012B (en) 2002-01-16 2012-04-30 Boehringer Ingelheim Pharma Gmbh&Co.Kg. TWO-TABLET PHARMACEUTICAL TABLE CONTAINING TELMISARTAN AND DIURETIC AND ITS PREPARATION
WO2003061602A2 (en) * 2002-01-24 2003-07-31 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
DE60315023T2 (de) 2002-04-26 2008-04-03 Gilead Sciences, Inc., Foster City Anreicherung in der zelle an phosphonat analoga von hiv protease inhibitor verbindungen und die verbindungen selbst
CN100406017C (zh) 2002-12-09 2008-07-30 佐治亚大学研究基金会 用于对抗hiv抗性株的二氧戊环基胸腺嘧啶及其组合物
DK1575566T3 (da) 2002-12-26 2012-03-26 Pozen Inc Flerlagsdoseringsformer indeholdende naproxen og triptaner
CN105596356A (zh) 2003-01-14 2016-05-25 吉里德科学公司 用于联合抗病毒治疗的组合物和方法
KR101125268B1 (ko) 2003-06-06 2012-04-23 에띠팜 구강 분산성 다중층 정제
CA2598607A1 (en) 2005-01-18 2006-07-27 Adra N. Chaker Methods and compositions for cell-cycle regulation
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
EP1899332A1 (en) 2005-06-24 2008-03-19 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c.
JP2009514790A (ja) * 2005-07-22 2009-04-09 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Ｈｉｖ−１−感染患者におけるウイルス負荷を減少させる方法
US7448494B2 (en) * 2005-08-10 2008-11-11 Certain Teed Corporation Loose fill insulation packaged with additive
KR20080091767A (ko) 2005-12-14 2008-10-14 씨아이피엘에이 엘티디. (테노포비어 및 라미뷰딘과 같은) 뉴클레오티드 역전사효소억제제 및 뉴클레오시드 역전사효소 억제제를 투여 단위의상이한 부분에 포함하는 약제학적 조합물
GB0525898D0 (en) 2005-12-20 2006-02-01 Pharmo Bioscience As Screening compounds for activity in modulating chloride ion transport
JP2010515771A (ja) 2007-01-16 2010-05-13 プロテオロジクス リミテッド トポイソメラーゼインヒビターの治療効果を増強する方法
EP2361247A4 (en) 2008-08-06 2012-08-08 Bionevia Pharmaceuticals Inc FLUPIRTINHYDROCHLORID-maleic acid co-crystal
WO2012003413A1 (en) 2010-06-30 2012-01-05 The Broad Institute, Inc. Novel solid forms of tacedinaline
BR112013012245B1 (pt) 2010-11-19 2022-09-27 Janssen Sciences Ireland Uc Comprimido compreendendo hcl de rilpivirina e fumarato de tenofovir disoproxila seu uso no tratamento profilático ou terapêutico de uma infecção por hiv

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2789331C2 (ru) * 2015-02-13 2023-02-01 Ховионе Сциентиа Лимитед Новые полиморфные формы миноциклинового основания и способы их получения
RU2786524C2 (ru) * 2018-09-28 2022-12-21 Акционерное общество "БИОКАД" Ингибиторы рецептора эпидермального фактора роста

Also Published As

Publication number Publication date
EP3025718A1 (en) 2016-06-01
EP1583542A1 (en) 2005-10-12
AU2004206827A1 (en) 2004-08-05
US20090143314A1 (en) 2009-06-04
NO20150656A1 (no) 2005-10-13
US9744181B2 (en) 2017-08-29
NO20053817D0 (no) 2005-08-12
US20060246130A1 (en) 2006-11-02
US20090036408A1 (en) 2009-02-05
CA2512475A1 (en) 2004-08-05
US8592397B2 (en) 2013-11-26
WO2004064845A8 (en) 2004-09-23
JP2017057232A (ja) 2017-03-23
AU2009200414A1 (en) 2009-02-26
KR20050092755A (ko) 2005-09-22
CA2512475C (en) 2009-06-02
JP2021004264A (ja) 2021-01-14
AU2009200414B2 (en) 2011-12-08
US9457036B2 (en) 2016-10-04
CA2512319A1 (en) 2004-08-05
EP1923063A3 (en) 2009-04-08
US20040224916A1 (en) 2004-11-11
US20040224917A1 (en) 2004-11-11
CN102670629A (zh) 2012-09-19
NZ540728A (en) 2008-08-29
WO2004064845A1 (en) 2004-08-05
US20170273994A1 (en) 2017-09-28
DE602004014470D1 (de) 2008-07-31
US20060234982A1 (en) 2006-10-19
DK1583542T3 (da) 2008-09-22
PL408254A1 (pl) 2014-07-21
AU2004206821A1 (en) 2004-08-05
HRP20050619A2 (en) 2005-10-31
SI1583542T1 (sl) 2008-12-31
US20140213556A1 (en) 2014-07-31
HRP20140379A2 (hr) 2014-07-18
JP2006516570A (ja) 2006-07-06
NO337917B1 (no) 2016-07-11
AU2004206821C1 (en) 2009-10-01
EP1585527A1 (en) 2005-10-19
CN105596356A (zh) 2016-05-25
MXPA05007016A (es) 2005-09-12
CN102670629B (zh) 2016-02-24
ATE398455T1 (de) 2008-07-15
JP2010120957A (ja) 2010-06-03
EP1583542B1 (en) 2008-06-18
EA015145B1 (ru) 2011-06-30
JP4996241B2 (ja) 2012-08-08
JP2006515624A (ja) 2006-06-01
KR20090053867A (ko) 2009-05-27
US20150111855A1 (en) 2015-04-23
BRPI0406760A (pt) 2005-12-20
US8716264B2 (en) 2014-05-06
PL378368A1 (pl) 2006-04-03
AP2089A (en) 2010-01-11
JP2019052174A (ja) 2019-04-04
JP2015098488A (ja) 2015-05-28
NO20171193A1 (no) 2005-10-13
EP1583542B9 (en) 2008-10-22
NO340951B1 (no) 2017-07-24
NO20053817L (no) 2005-10-13
HK1079122A1 (en) 2006-03-31
AP2005003348A0 (en) 2005-06-30
AU2004206821B2 (en) 2009-02-26
ES2308136T3 (es) 2008-12-01
IS7977A (is) 2005-08-12
JP2014037430A (ja) 2014-02-27
CY1108355T1 (el) 2014-02-12
KR20080032014A (ko) 2008-04-11
IL169243A (en) 2008-12-29
KR100860136B1 (ko) 2008-09-25
EP1923063A2 (en) 2008-05-21
US20170232019A1 (en) 2017-08-17
EA201100293A1 (ru) 2011-08-30
WO2004064846A1 (en) 2004-08-05
US20150111856A1 (en) 2015-04-23
PT1583542E (pt) 2008-09-17

Similar Documents

Publication Publication Date Title
EA200501134A1 (ru) Способ профилактики и лечения вирусных инфекций (варианты), фармацевтическая композиция (варианты) и лечебный набор
CY1124720T1 (el) Απο του στοματος σκευασματα αναλογων κυτιδινης και μεθοδοι χρησης αυτων
CY1122336T1 (el) Eνωσεις πυρρολιου ως αναστολεις πρωτεϊνικων κινασων εrκ και φαρμακευτικες συνθεσεις που περιεχουν αυτες τις ενωσεις
CY1111709T1 (el) Προϊοντα συζευξης φωσφονικου νουκλεοσιδιου ως αντι hiv παραγοντες
CY1124914T1 (el) Στερεες φαρμακευτικες συνθεσεις που περιεχουν αναστολεα ιντεγκρασης
EA200970273A1 (ru) Применение 2-6-(3-аминопиперидин-1-ил)-3-метил-2,4-диоксо-3,4-дигидро-2н-пиримидин-1-илметил-4-фторбензонитрила
EA201201265A1 (ru) Композиция (варианты), способ ее получения, резервуар, содержащий указанную композицию, и способ лечения вирусных заболеваний с ее использованием
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
EA200800726A1 (ru) Введение ингибиторов дипептидилпептидазы
EA200970851A1 (ru) Еженедельное введение ингибиторов дипептидилпептидазы
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
JP2019511542A5 (ru)
EA201500431A1 (ru) Соединения боронатного эфира и его фармацевтические составы
EA201491180A1 (ru) 4'-азидо,3'-фторзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гепатита с
EA201171376A1 (ru) Производные тиено[2,3-b]пиридина в качестве ингибиторов репликации вируса
HRP20050633A2 (en) Formulation and methods for the treatment of thrombocythemia
MX2019008118A (es) Nuevas formas solidas de acetato de[(1s)-1-[(2s,4r,5r)-5-(5-amino- 2-oxo-tiazolo[4,5-d]pirimidin-3-il)-4-hidroxi tetrahidrofuran-2-il]propilo].
RU2013148627A (ru) Производные тиено [2, 3-d] пиримидина и их применение для лечения аритмии
ZA200505852B (en) Compositions and methods for combination antiviraltherapy
NZ601519A (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION comprising lamivudine and adefovir dipivoxil
AR022462A1 (es) Uso de un agente que disminuye el colesterol
AR101679A2 (es) Composiciones para el tratamiento antiviral combinado
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
MX2021011614A (es) Formas solidas de un compuesto del modificador alosterico de la proteina del nucleo del vhb.
AR026255A1 (es) Combinaciones antivirales.

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent
ND4A Extension of term of a eurasian patent
MH4A Revocation of a eurasian patent in part
MA4A Surrender of the eurasian patent at the request of the proprietor in the following designated state(s)

Designated state(s): KZ

MF4A Revocation of a eurasian patent as invalid entirely

Designated state(s): KZ